Stock CRNX CRINETICS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
47.2 USD +0.90% Intraday chart for Crinetics Pharmaceuticals, Inc. +12.06% +32.66%
04-17 Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing MT
03-26 Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly
Crinetics Pharmaceuticals Up in Extended Hours After Positive Top-Line Results for Drug Candidate
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Crinetics Pharmaceuticals to Raise $350 Million via Private Placement
Crinetics Pharmaceuticals Insider Sold Shares Worth $354,700, According to a Recent SEC Filing
Crinetics Pharmaceuticals Shares Rise After Positive Initial Phase 2 Data for Paltusotine to Treat Carcinoid Syndrome
Crinetics Pharmaceuticals' Initial Phase 2 Data of Paltusotine for Carcinoid Syndrome Shows Reductions in Bowel Movements
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Crinetics Pharmaceuticals CEO Sold Shares Worth $6,111,440, According to a Recent SEC Filing
Crinetics Pharmaceuticals Insider Sold Shares Worth $210,000, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRNX Stock
  4. News Crinetics Pharmaceuticals, Inc.
  5. Other languages